{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:10:28Z","timestamp":1790784628365,"version":"4.1.0"},"reference-count":58,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":272,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100019004","name":"Deanship of Research, Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["44\/2024"],"award-info":[{"award-number":["44\/2024"]}],"id":[{"id":"10.13039\/501100019004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>The current study aimed to improve the dissolution rate and physical stability of two antihypertensive drugs, hydrochlorothiazide, and valsartan, through the development of a co\u2010amorphous system. A co\u2010amorphous system was successfully prepared at molar ratios of 1:1, 1:2, and 1:6 employing rotary evaporation technique. Characterization of the formulations was performed using powder X\u2010ray diffraction, differential scanning calorimetry, Fourier transform infrared spectroscopy, and thermogravimetric analysis. Powder X\u2010ray diffraction confirmed the amorphous nature of all samples, which remained physically stable under ambient dry conditions for at least 8\u2009months. Differential scanning calorimetry confirmed the formation of a single\u2010phase system. The experimental glass transition temperature values revealed a negative deviation from those calculated by the Gordon\u2013Taylor equation, indicating nonideal mixing and intermolecular interactions. Fourier transform infrared spectroscopy spectra supported these findings, showing peak broadening in regions corresponding to the functional groups of the parent drugs. The thermogravimetric analysis demonstrated that the samples were thermally stable, with no degradation observed up to 100\u00b0C. Dissolution studies performed in phosphate buffer (pH 6.8, 25\u00b0C) revealed significant enhancements in the dissolution rates of both hydrochlorothiazide and valsartan from the co\u2010amorphous formulations compared to their unprocessed forms and corresponding physical mixtures. A validated high\u2010performance liquid chromatography method was developed for the simultaneous analysis of hydrochlorothiazide and valsartan using a Shimadzu LC\u20102030C 3D Plus system with a photodiode array detector. Separation was achieved on a Waters C18 column (250\u2009\u00d7\u20094.6\u2009mm, 5\u2009\u03bcm) using a mobile phase of acetonitrile, methanol, and ammonium acetate buffer (20:50:30, v\/v) at a flow rate of 0.70\u2009mL\/min. Detection wavelengths were set at 271\u2009nm for hydrochlorothiazide and 249\u2009nm for valsartan. The method showed good linearity in the range from 0.0033 to 0.0670\u2009mM (3.3\u201367.0\u2009\u03bcM), precision (RSD &lt;\u20092%), and reproducibility, with hydrochlorothiazide and valsartan eluting at 3.5 and 7.2\u2009min, respectively. At the first minute, hydrochlorothiazide release increased by approximately 8.5\u2010, 8.7\u2010, and 7.1\u2010fold from the 1:1, 1:2, and 1:6 co\u2010amorphous systems relative to the unprocessed drug, and by 4.5\u2010, 4.8\u2010, and 2.4\u2010fold, respectively, compared to the corresponding physical mixtures. For valsartan, the co\u2010amorphous systems showed 2.9\u2010, 2.6\u2010, and 1.9\u2010fold improvements over the unprocessed drug, and 1.5\u2010, 1.8\u2010, and 1.5\u2010fold improvements over the matching physical mixtures at the same molar ratios. Calcium carbonate was physically mixed with all samples to minimize gelation upon aqueous exposure. These results suggest that co\u2010amorphous formulation is a promising strategy for enhancing the dissolution rate and physical stability of hydrochlorothiazide and valsartan.<\/jats:p>","DOI":"10.1155\/adpp\/9387077","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:40:40Z","timestamp":1790782840000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dissolution Rate and Stability Improvement of Hydrochlorothiazide and Valsartan by Co\u2010Amorphous Formulation"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9963-8625","authenticated-orcid":false,"given":"Asal M.","family":"Abdulraheem","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology Faculty of Pharmacy Jordan University of Science and Technology  Irbid Jordan  just.edu.jo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8222-9209","authenticated-orcid":false,"given":"Khouloud A.","family":"Alkhamis","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology Faculty of Pharmacy Jordan University of Science and Technology  Irbid Jordan  just.edu.jo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-0158","authenticated-orcid":false,"given":"Suhair S.","family":"Al-Nimry","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology Faculty of Pharmacy Jordan University of Science and Technology  Irbid Jordan  just.edu.jo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2006.04.010"},{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2004.02.001"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.04.066"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/js9601896"},{"key":"e_1_2_8_5_2","first-page":"331","article-title":"Polymorphism in Pharmaceutical Solids","volume":"95","author":"Brittain H. G.","year":"1999","journal-title":"Drugs and the Pharmaceutical Sciences"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2009.01.018"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.9.866"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600600902"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.09.005"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22074"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.01.008"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103980"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12550"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101682"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.08.003"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00224"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00272"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b01014"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.10.019"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.08.015"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(99)00096-9"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2008.07.011"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp2002973"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpcb.8b06306"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.05.007"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.09.003"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.18433\/j3p30b"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10837450.2015.1098635"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-015-0398-4"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-016-0674-3"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105773"},{"key":"e_1_2_8_32_2","doi-asserted-by":"crossref","unstructured":"LodagekarA. ChavanR. B. ChaitanyaM. K.et al. Co-amorphous valsartan\u2013nifedipine System: Preparation Characterization in Vitro and in Vivo Evaluation European Journal of Pharmaceutical Sciences 139 no. 2019 https:\/\/doi.org\/10.1016\/j.ejps.2019.105048.","DOI":"10.1016\/j.ejps.2019.105048"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.cgd.7b01518"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010040"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00135"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11120628"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262130-00007"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22197"},{"key":"e_1_2_8_39_2","first-page":"8","article-title":"Solubility Enhancement Studies of Hydrochlorothiazide by Preparing Solid Dispersions Using Losartan Potassium and Urea by Different Methods","volume":"3","author":"Trivedi R. V.","year":"2011","journal-title":"Der Pharmacia Lettre"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.08.052"},{"key":"e_1_2_8_41_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0099-5428(08)60646-2","article-title":"Hydrochlorothiazide","volume":"10","author":"Deppeler H. P.","year":"1981","journal-title":"Analytical Profiles of Drug Substances"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.podrm.2015.02.001"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/cg400287n"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.12.009"},{"key":"e_1_2_8_45_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/9781118971147.ch5","volume-title":"ICH Quality Guidelines: An Implementation Guide","author":"Borman P.","year":"2017"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.11.037"},{"key":"e_1_2_8_47_2","doi-asserted-by":"crossref","DOI":"10.1002\/9783527831708","volume-title":"Method Validation in Pharmaceutical Analysis: A Guide to Best Practice","author":"Ermer J.","year":"2025"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2024.101469"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13738-022-02585-3"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82116-8https:\/\/do"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr0302049"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106083"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00652"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122644"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124592"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121019"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja027357n"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2602-5"}],"container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/adpp\/9387077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/adpp\/9387077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/adpp\/9387077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:43:27Z","timestamp":1790783007000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/adpp\/9387077"}},"subtitle":[],"editor":[{"given":"Anjali","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/adpp\/9387077"],"URL":"https:\/\/doi.org\/10.1155\/adpp\/9387077","archive":["Portico"],"relation":{},"ISSN":["2633-4682","2633-4690"],"issn-type":[{"value":"2633-4682","type":"print"},{"value":"2633-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"9387077"}}